Department of Emergency Medicine, Wayne State University, Detroit, Michigan, USA.
Integrative Biosciences Center, Clinical Research Division, Wayne State University, Detroit, Michigan, USA.
Am J Hypertens. 2020 Sep 10;33(9):837-845. doi: 10.1093/ajh/hpaa108.
Subclinical hypertensive heart disease (SHHD) is a precursor to heart failure. Blood pressure (BP) reduction is an important component of secondary disease prevention in patients with SHHD. Treating patients with SHHD utilizing a more intensive BP target (120/80 mm Hg), may lead to improved cardiac function but there has been limited study of this, particularly in African Americans (AAs).
We conducted a single center, randomized controlled trial where subjects with uncontrolled, asymptomatic hypertension, and SHHD not managed by a primary care physician were randomized to standard (<140/90 mm Hg) or intensive (<120/80 mm Hg) BP therapy groups with quarterly follow-up for 12 months. The primary outcome was the differences of BP reduction between these 2 groups and the secondary outcome was the improvement in echocardiographic measures at 12 months.
Patients (95% AAs, 65% male, mean age 49.4) were randomized to the standard (n = 65) or the intensive (n = 58) BP therapy groups. Despite significant reductions in systolic BP (sBP) from baseline (-10.9 vs. -19.1 mm Hg, respectively) (P < 0.05), no significant differences were noted between intention-to-treat groups (P = 0.33) or the proportion with resolution of SHHD (P = 0.31). However, on post hoc analysis, achievement of a sBP <130 mm Hg was associated with significant reduction in indexed left ventricular mass (-6.91 gm/m2.7; P = 0.008) which remained significant on mixed effect modeling (P = 0.031).
In post hoc analysis, sBP <130 mm Hg in predominantly AA patients with SHHD was associated with improved cardiac function and reverse remodeling and may help to explain preventative effects of lower BP goals.
Trial Number NCT00689819.
亚临床高血压性心脏疾病(SHHD)是心力衰竭的前兆。降低血压(BP)是 SHHD 患者二级疾病预防的重要组成部分。针对 SHHD 患者采用更严格的 BP 目标(120/80mmHg)进行治疗,可能会改善心脏功能,但对此研究甚少,尤其是在非裔美国人(AA)中。
我们开展了一项单中心、随机对照试验,将未经控制的、无症状的高血压且未接受初级保健医生管理的 SHHD 患者随机分为标准(<140/90mmHg)或强化(<120/80mmHg)BP 治疗组,每季度随访 12 个月。主要结局为两组间 BP 降低的差异,次要结局为 12 个月时超声心动图测量指标的改善。
患者(95%为 AA,65%为男性,平均年龄 49.4 岁)被随机分为标准(n=65)或强化(n=58)BP 治疗组。尽管收缩压(sBP)从基线显著降低(分别为-10.9 与-19.1mmHg)(P<0.05),但意向治疗组间无显著差异(P=0.33)或 SHHD 缓解比例(P=0.31)。然而,事后分析显示,sBP<130mmHg 与左心室质量指数(LVMI)显著降低相关(-6.91gm/m2.7;P=0.008),混合效应模型分析仍具有统计学意义(P=0.031)。
在事后分析中,SHHD 的 AA 患者 sBP<130mmHg 与心脏功能改善和逆向重构相关,可能有助于解释更低 BP 目标的预防作用。
试验编号 NCT00689819。